| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communication |











From the Vancouver Vascular Biology Research Centre-St. Paul's
Hospital,*
Vancouver, British Columbia, Canada; the
Department of Pathology and Laboratory
Medicine,
University of British Columbia,
Vancouver, British Columbia, Canada; and QLT PhotoTherapeutics
Inc.,
Vancouver, British Columbia, Canada
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
A diverse range of stimuli can induce EC apoptosis. In the current study, Photodynamic therapy (PDT) was used as a method to induce apoptosis in human umbilical venous endothelial cells (HUVECs). PDT, using the photosensitizer verteporfin, catalyzes the formation of reactive oxygen intermediates and has been used as a tool to rapidly induce apoptosis in a variety of cell types following light irradiation.9-14 PDT is a clinically approved modality for the treatment of various types of cancer. One of the primary targets of PDT during tumor eradication is the tumor neovasculature.15 PDT is also being investigated for the treatment of atherosclerosis, restenosis, and age-related macular degeneration. However, the effects of PDT on EC apoptosis are poorly understood. In the present report, several novel aspects of EC apoptosis are described, including the cellular redistribution of cytochrome c and Bax followed by the activation of multiple caspases resulting in the downstream cleavage of Bid.
| Materials and Methods |
|---|
|
|
|---|
Lipid-formulated verteporfin was provided by QLT PhotoTherapeutics Inc. (Vancouver, BC). Antibodies were obtained from the following sources: caspases 1, 6, and 8 (Upstate Biotechnology Inc., Lake Placid, NY); Bid, caspase 3 (Santa Cruz Biotechnology Inc., Santa Cruz, CA); caspase 7 (Transduction Laboratories, Mississauga, ON); cytochrome c, Bax, caspases 2, 4, 9, and 10 (Pharmingen, Mississauga, ON); poly(ADP-ribose) polymerase (PARP) (Biomol Research Laboratories, Plymouth Meeting, PA).
Cell Culture
HUVECs (Clonetics, San Diego, CA) were maintained in endothelial basal medium (EBM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), hydrocortisone (1 µg/ml), bovine brain extract (12 µg/ml), gentamicin (50 µg/ml), amphotericin B (50 ng/ml), and epidermal growth factor (10 ng/ml) (Clonetics).
Photoactivation of Verteporfin
HUVECs (5 x 106) were incubated for 60 minutes in the dark at 37°C with or without verteporfin (100 ng/ml) in EBM supplemented with 2% FBS. For caspase inhibition studies, 50 µmol/L Z-Val-Ala-Asp-fluoromethylketone (ZVAD-fmk) (Bachem, Torrance, CA) was added to cells for the final 30 minutes of the verteporfin incubation period before light activation. After drug incubation, cells were exposed to fluorescent red light (620700 nm) delivered at a rate of 5.6 mW/cm2 to give a total dose of 2 J/cm2. Cells were then maintained in Petri dishes at 37°C until further analysis.
Immunoblot Analysis
Whole and cytosolic (S-100) cell extracts were prepared as previously described.13 Protein concentrations were measured using the Pierce BCA protein assay (Pierce, Rockford, IL). Detergent soluble proteins (30 µg) were separated by SDS-PAGE in 10 to 12% acrylamide gels under reducing conditions followed by Western blotting as described.13 After transfer of protein from the gel to the membrane, gels were stained with 20 ml of Gel-Code Blue stain reagent (Pierce) to ensure equal loading was achieved in each well.
Immunofluorescence
HUVECs were grown on collagen-coated 8-well chamber slides. After treatment with either media alone or 2 hours after PDT (100 ng/ml verteporfin; 2 J/cm2 red light, 620700 nm), cells were coated with acetone for 20 minutes at -20°C. Cells were then washed with PBS and incubated with 5% skim milk powder in PBS for 30 minutes at 37°C. Cells were washed with PBS and incubated with or without (not shown) rabbit anti-active caspase 3 antibody (Pharmingen) (1:20) for 30 minutes at 37°C. Cells were washed and incubated with 1% normal goat serum for 30 minutes at 37°C. Goat serum (Biosource, Camarillo, CA) was removed and goat anti-rabbit IgG FITC-conjugated antibody (Biosource, Camarillo, CA) (1:100) in 0.1% normal goat serum was added for 30 minutes at 37°C. Wells were coated with 100 µl of Antifade reagent (Molecular Probes; Eugene, Oregon). Fluorescent images were acquired through a standard FITC filter set (Omega, Brattleboro, VT)using a 16-bit cooled CCD camera (1024 x 1024 pixels; Photometrics, Tucson, AZ) mounted on 2.5x adapter at the bottom port of an Axiovert S100 TV microscope (Zeiss, North York, ON, Canada) and coupled to the signal acquisition and processing software SlideBook (Intelligent Imaging Innovations, Denver, CO). A 63x Zeiss objective was used for obtaining detailed pictures.
| Results |
|---|
|
|
|---|
Western blot analysis of whole cell protein extracts indicated
that the overall expression level and molecular mass of Bax and
cytochrome c did not change, whereas Bid was undetectable by
2 hours after irradiation (Figure 1A)
.
However, cytosolic (S-100) levels of Bax decreased and it was not
detectable by 2 hours after treatment. In contrast, cytosolic
cytochrome c was evident immediately and its levels
increased over 2 hours after treatment (Figure 1A)
. Morphological
evidence of apoptosis was not observed before the initial release of
cytochrome c and decrease in cytosolic Bax (data not shown).
|
Caspase 1, 2, 3, 4, 6, 7, 8, 9, and 10 activation were assessed
using Western blotting. Processing of caspases, as determined by either
the disappearance of the proform of the enzyme and/or detection of one
of the cleavage intermediates or active subunits (caspase 2, 3, 8, and
9 only), was apparent for caspases 2, 3, 6, 7, 8, and 9 within 1 to 2
hours after treatment (Figure 1B)
. Caspase 1, 4, or 10 processing was
not detected (data not shown).
Inhibition of HUVEC Apoptosis with ZVAD-fmk
HUVECs were incubated with a general caspase family inhibitor
(ZVAD-fmk) before photoactivation of verteporfin. Differential
interference contrast (DIC) microscopy was used to visualize the effect
of ZVAD-fmk on cell morphology (Figure 2A)
. ZVAD-fmk completely blocked the cell
shrinkage and membrane blebbing effects that are commonly associated
with apoptosis. ZVAD-fmk blocked caspase 3 processing and subsequent
PARP cleavage indicating that ZVAD-fmk was effective at interfering
with HUVEC apoptosis (Figure 2B)
. Verteporfin in the absence of light
did not induce caspase 3 activation, PARP cleavage, cell shrinkage or
membrane blebbing.
|
| Discussion |
|---|
|
|
|---|
It has been suggested that once mitochondrial cytochrome c
is released into the cytosol, the cell may be irreversibly committed to
death.9
The mechanism by which cytochrome c is
released into the cytosol is not understood, but may involve the
opening of a mitochondrial megachannel known as the mitochondrial
permeability transition pore.9
In the case of EC
apoptosis, this pore may be sensitive to cyclosporin A.8
OxLDL, tumor necrosis factor-
, and angiotensin II induce the release
of mitochondrial cytochrome c, an event which can be
inhibited by pretreatment with cyclosporin A.8
Our studies confirm observations of other investigators that caspase 3 is activated during EC apoptosis. We further demonstrate that several other caspases participate in the execution of apoptosis downstream of cytochrome c release. We clearly demonstrate for the first time the activation of caspases 2, 6, 7, 8, and 9 during HUVEC apoptosis. Biochemical analysis has revealed that caspase 9 may be the first caspase activated following cytochrome c release.21 Cytochrome c is believed to be necessary for Apaf-1-mediated processing of caspase 9, which, in turn, cleaves other downstream executioner caspases.21 Caspase 3 is one of the best characterized caspases and has been termed the "central executioner" of apoptosis. On activation, caspase 3 can cleave numerous proteins involved in cell structure, signaling, and repair and is essential for DNA fragmentation.4 Caspase 3 may also facilitate the activation of caspase 2.22 Caspase 8 processing, as evidenced by the appearance of 43- and 41-kd caspase 8a/b intermediate cleavage products, is further exemplified by the disappearance of Bid, a known caspase 8 substrate.18,19 Activation of caspase 8 downstream of cytochrome c release, followed by Bid cleavage, offers a potential positive feedback mechanism to enhance further cytochrome c release during drug-induced apoptosis. Caspase 6, its activation evidenced by the disappearance of its proform, may participate in the cleavage of lamins, major constituents of the nuclear envelope.23 Caspase 7 appears to have a similar role and substrate preference to caspase 3.3
In summary, EC apoptosis is associated with decreased cytosolic levels of Bax, and increased cytosolic levels of cytochrome c. The appearance of cytochrome c in the cytosol precedes the activation of multiple caspases, which are ultimately responsible for cleaving various structural, functional, and reparative proteins resulting in the manifestation of an apoptotic phenotype. Further understanding of the events that execute the apoptotic process once the cell is committed to death may be applicable to the understanding of the role of apoptosis, or lack thereof, in the pathogenesis and treatment of common vascular disorders.
| Footnotes |
|---|
Supported in part by the St. Paul's Hospital Foundation and a grant-in-aid from the Heart and Stroke Foundation of British Columbia and Yukon (DJG, BMM). DJG is a recipient of a Heart and Stroke Foundation of Canada traineeship. CMC is a recipient of a Heart and Stroke Foundation of British Columbia and Yukon traineeship.
Accepted for publication June 3, 1999.
| References |
|---|
|
|
|---|
but not CPP32: multiple interleukin 1ß-converting enzyme-related proteases with distinct substrate recognition properties are active in apoptosis. Proc Natl Acad Sci USA 1996, 93:8395-8400This article has been cited by other articles:
![]() |
J. Jiang, R. Goel, M. A. Iftekhar, R. Visaria, J. D. Belcher, G. M. Vercellotti, and J. C. Bischof Tumor necrosis factor-{alpha}-induced accentuation in cryoinjury: mechanisms in vitro and in vivo Mol. Cancer Ther., August 1, 2008; 7(8): 2547 - 2555. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Cao, R. L. Bennett, and W. S. May c-Myc and Caspase-2 Are Involved in Activating Bax during Cytotoxic Drug-induced Apoptosis J. Biol. Chem., May 23, 2008; 283(21): 14490 - 14496. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Matsubara, T. Nakazawa, K. Noda, H. She, E. Connolly, T. A. Young, Y. Ogura, E. S. Gragoudas, and J. W. Miller Photodynamic Therapy Induces Caspase-Dependent Apoptosis in Rat CNV Model Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4741 - 4747. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Luo, Z. Xia, D. M. Ansley, J. Ouyang, D. J. Granville, Y. Li, Z.-Y. Xia, Q.-S. Zhou, and X.-Y. Liu Propofol Dose-Dependently Reduces Tumor Necrosis Factor-{alpha}-Induced Human Umbilical Vein Endothelial Cell Apoptosis: Effects on Bcl-2 and Bax Expression and Nitric Oxide Generation Anesth. Analg., June 1, 2005; 100(6): 1653 - 1659. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Savellano and T. Hasan Photochemical Targeting of Epidermal Growth Factor Receptor: A Mechanistic Study Clin. Cancer Res., February 15, 2005; 11(4): 1658 - 1668. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Gardai, D. A. Hildeman, S. K. Frankel, B. B. Whitlock, S. C. Frasch, N. Borregaard, P. Marrack, D. L. Bratton, and P. M. Henson xPhosphorylation of Bax Ser184 by Akt Regulates Its Activity and Apoptosis in Neutrophils J. Biol. Chem., May 14, 2004; 279(20): 21085 - 21095. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Cao, X. Deng, and W. S. May Cleavage of Bax to p18 Bax accelerates stress-induced apoptosis, and a cathepsin-like protease may rapidly degrade p18 Bax Blood, October 1, 2003; 102(7): 2605 - 2614. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Fanzo, S. K. Reaves, L. Cui, L. Zhu, and K. Y. Lei p53 protein and p21 mRNA levels and caspase-3 activity are altered by zinc status in aortic endothelial cells Am J Physiol Cell Physiol, August 1, 2002; 283(2): C631 - C638. [Abstract] [Full Text] [PDF] |
||||
![]() |
R Mansfield, S Bown, and J McEwan Photodynamic therapy: shedding light on restenosis Heart, December 1, 2001; 86(6): 612 - 618. [Full Text] [PDF] |
||||
![]() |
D. J. Granville, B. A. Cassidy, D. O. Ruehlmann, J. C. Choy, C. Brenner, G. Kroemer, C. van Breemen, P. Margaron, D. W. Hunt, and B. M. McManus Mitochondrial Release of Apoptosis-Inducing Factor and Cytochrome c During Smooth Muscle Cell Apoptosis Am. J. Pathol., July 1, 2001; 159(1): 305 - 311. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H. J. M. PIJPERS, P. A. V. SETTEN, L. P. W. J. V. D. HEUVEL, K. J. M. ASSMANN, H. B. P. M. DIJKMAN, A. H. M. PENNINGS, L. A. H. MONNENS, and V. W. M. V. HINSBERGH Verocytotoxin-Induced Apoptosis of Human Microvascular Endothelial Cells J. Am. Soc. Nephrol., April 1, 2001; 12(4): 767 - 778. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-S. Belzacq, E. Jacotot, H. L. A. Vieira, D. Mistro, D. J. Granville, Z. Xie, J. C. Reed, G. Kroemer, and C. Brenner Apoptosis Induction by the Photosensitizer Verteporfin: Identification of Mitochondrial Adenine Nucleotide Translocator as a Critical Target Cancer Res., February 1, 2001; 61(4): 1260 - 1264. [Abstract] [Full Text] |
||||
![]() |
M. Tafani, T. G. Schneider, J. G. Pastorino, and J. L. Farber Cytochrome c-Dependent Activation of Caspase-3 by Tumor Necrosis Factor Requires Induction of the Mitochondrial Permeability Transition Am. J. Pathol., June 1, 2000; 156(6): 2111 - 2121. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |